Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.

SEC Filings

For all investor or media inquiries, visit https://www.adaptimmune.com/contact.

Filing date	Description	Form	Filing Group	View
Sep 01, 2022	A statement of beneficial ownership of common stock by certain persons	SC 13G	Other	0001461790-22-000022.pdf 0001461790-22-000022.rtf 0001461790-22-000022.xls View HTML
Aug 28, 2019	Additional proxy soliciting materials - definitive	DEFA14A	Proxy Filings	0001750019-19-000053.pdf 0001750019-19-000053.rtf 0001750019-19-000053.xls View HTML
Aug 14, 2020	Additional proxy soliciting materials - definitive	DEFA14A	Proxy Filings	0001193125-20-220342.pdf 0001193125-20-220342.rtf 0001193125-20-220342.xls View HTML
Sep 03, 2021	Additional proxy soliciting materials - definitive	DEFA14A	Proxy Filings	0001193125-21-265554.pdf 0001193125-21-265554.rtf 0001193125-21-265554.xls View HTML
Sep 01, 2022	Additional proxy soliciting materials - definitive	DEFA14A	Proxy Filings	0001193125-22-236510.pdf 0001193125-22-236510.rtf 0001193125-22-236510.xls View HTML
May 22, 2023	Additional proxy soliciting materials - definitive	DEFA14A	Proxy Filings	0001104659-23-062928.pdf 0001104659-23-062928.rtf 0001104659-23-062928.xls View HTML
May 24, 2023	Additional proxy soliciting materials - definitive	DEFA14A	Proxy Filings	0001193125-23-153028.pdf 0001193125-23-153028.rtf 0001193125-23-153028.xls View HTML
Feb 01, 2019	Amended Registration statement for face-amount certificate companies	S-1/A	Registration Statements	0001193125-19-025782.pdf 0001193125-19-025782.rtf 0001193125-19-025782.xls View HTML
Feb 13, 2019	Amended Registration statement for face-amount certificate companies	S-1/A	Registration Statements	0001193125-19-037835.pdf 0001193125-19-037835.rtf 0001193125-19-037835.xls View HTML
Nov 18, 2022	Amendment to a previously filed SC TO-I	SC TO-I/A	Other	0001193125-22-288949.pdf 0001193125-22-288949.rtf 0001193125-22-288949.xls View HTML

Data provided by Kaleidoscope.

Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.